HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.
May 15, 2024 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.
The reiteration of a Buy rating and the maintenance of a price target at $18 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100